**DiseaseINFOPACK: Streptococcus dysgalactiae (SDSE)** (CAT: VADIP016)

<table>
<thead>
<tr>
<th>Proposal No/#PO</th>
<th>[Enter client specific #PO]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>Comprehensive review/analysis of S. dysgalactiae (SDSE) disease trends/dynamics</td>
</tr>
<tr>
<td>Project Initiation Date</td>
<td>n/a</td>
</tr>
<tr>
<td>Billable days</td>
<td>n/a</td>
</tr>
<tr>
<td>Initiator(s)</td>
<td>[Enter client name, function and address]</td>
</tr>
<tr>
<td>Therapeutic Area</td>
<td>Streptococcal infections</td>
</tr>
<tr>
<td>Product (if applicable)</td>
<td>CAT No: VADIP016, published September 2009</td>
</tr>
</tbody>
</table>

**Background**

*Streptococcus dysgalactiae* subsp. Equisimilis (SDSE) is a usually a beta-hemolytic commensal organism found in the human throat and skin which can cause a spectrum of human diseases similar to *Streptococcus pyogenes* or Group A Streptococcus (GAS) (1). These diseases include superficial skin infections, pharyngitis and life threatening conditions such as Streptococcal toxic shock syndrome (STSS).

SDSE may express group A, group C or group G Lancefield antigens, but generally SDSE expressing group C antigen (GGS) is the most common form of human disease. Unlike invasive disease due to GAS, SDSE infections are not notifiable in most countries with only the UK (Health Protection Agency) reporting bacteremia split by subtype.

This expert DiseaseINFOPACK report is a comprehensive up-to-date review of current literature regarding SDSE across EU, US and “Rest of World regions”. It will allow the reader to quickly grasp current understanding regarding SDSE and help ascertain disease dynamics/trends relative to other important causes of invasive and non-invasive infections in immunocompromised groups. The report may guide novel antibiotic development and/or passive immunotherapeutics.

PRODUCT CONTENTS:

Published September 2009 (CAT No: VADIP016)

Executive summary
The pathogen
Pathogenesis
Spectrum of disease
Spectrum of disease: Pharyngitis
Spectrum of disease: Invasive disease
Host response
Risk groups
Transmission
Treatment
Prevention and control
Surveillance
Epidemiology: Incidence
Epidemiology: US
Epidemiology: Canada
Epidemiology: UK
Epidemiology: Germany
Epidemiology: Finland
Epidemiology: Denmark
Epidemiology: Japan
Epidemiology: Taiwan
Epidemiology: summary
Mortality
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~52 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form
PROJECT METHODOLOGY:

VacZine Analytics has conducted a comprehensive secondary research to review all available information regarding SDSE in major Western (US + EU) and SE Asia markets. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

PRODUCT PRICE:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $4895.00/ GBP £3265.00 (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 15% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY:

37. Stelter K et al. [Lethal end of a group C streptococcal necrotizing fasciitis in a healthy female] Laryngorhinootologie. 2006 Mar;85(3):197-200.
58. Ukubata K et al. [Large-scale questionnaire surveillance concerning invasive infections with group C and G streptococci]. Kansenshogaku Zasshi. 2006 Sep;80(5):480-7.
TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.

5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on-line invoices are payable within thirty days of the invoice date.

7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master TERMS and CONDITIONS available upon request or at www.vaczine-analytics.com

VacZine Analytics
Of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009